Medications

PET imaging shows if PD-1 cancer immunotherapy is working

PD-1 is a protein on our T cells that normally keeps these immune cells from running amok. A growing number of cancer drugs are designed to inhibit PD-1, enabling patients' T-cells to attack and kill cancerous cells. PD-1 ...

Oncology & Cancer

Unlocking therapies for hard-to-treat lung cancers

Now, a new Salk Institute study, published on July 24, 2019, in the journal Science Advances, shows that researchers could target these hard-to-treat cancers by pursuing drugs that keep a cellular "switch," called CREB, from ...

Oncology & Cancer

Study identifies potential markers of lung cancer

By examining both blood samples and tumor tissues from patients with non-small-cell lung cancer (NSCLC), investigators at Massachusetts General Hospital (MGH) have identified markers that can distinguish between major subtypes ...

Oncology & Cancer

Pushing MYC inhibition closer to the clinic

Cutting-edge sequencing technology has revolutionized cancer diagnosis and since identified several so-called cancer driver genomic aberrations. This has led to the development of an extensive and powerful arsenal of anti-cancer ...

Oncology & Cancer

Checkmating tumors

Chess and cancer research have one thing in common: It takes strategy to defeat the opponent. And that's exactly what scientists at the MDC are doing. They are seeking to selectively make only those cancer cells aggressive ...

Oncology & Cancer

Nobel-winning therapy weaponises immune system against cancer

A revolutionary cancer treatment pioneered by the winners of the 2018 Nobel Prize for Medicine has been hailed as the future of fighting the disease—and it has fewer devastating side effects than chemotherapy.

page 1 from 18